3,4-dihydro-2,2-dimethyl-3-hydroxy-4-(1-piperidinyl)-6-amino-7-nitro-2H-benzo[b]pyran

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 3,4-dihydro-2,2-dimethyl-3-hydroxy-4-(1-piperidinyl)-6-amino-7-nitro-2H-benzo[b]pyran
• 英文别名: 6-amino-3,4-dihydro-2,2-dimethyl-7-nitro-trans-4-piperidino-2H-benzo[b]pyran-3-ol；3,4-dihydro-2,2-dimethyl-3-hydroxy-4-(1-piperidinyl)-6-amino-7-nitro-2H-benzo [b] pyran；6-amino-2,2-dimethyl-7-nitro-4-piperidin-1-yl-3,4-dihydrochromen-3-ol
• 化学式: C₁₆H₂₃N₃O₄
• 分子量: 321.376
• InChiKey: VZYRWTCQALJQGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3,4-dihydro-2,2-dimethyl-3-hydroxy-4-(1-piperidinyl)-6-amino-7-nitro-2H-benzo[b]pyran 在 palladium-carbon 作用下， 以 乙醇 为溶剂， 25.0 ℃ 、13.51 MPa 条件下， 反应 3.0h， 以to obtain 0.12 g (yield: 95%) of 3,4-dihydro-2,2-dimethyl-3-hydroxy-4-(1-piperidinyl)-6-,7-diamino-2H-benzo[b]pyran as a dark red oil的产率得到3,4-dihydro-2,2-dimethyl-3-hydroxy-4-(1-piperidinyl)-6,7-diamino-2H-benzo[b]pyran
  参考文献：
  名称：

  Medicines for cardiac insufficiency

  摘要：

  本发明涉及一种心脏强效药物，其活性成分包含式(I)化合物及其药学上可接受的盐，当它们形成盐时。其中，X^1和X^2不存在或代表氧原子；A代表OH或C1-C4酰氧基；B代表氢原子或与A形成化学键；X代表氧原子、氮、硫等；R^1和R^2各代表氢原子、C1-C4烷基等；R^3和R^4各代表氢原子、C1-C4烷基等，或它们可以共同形成1,4-丁二亚基或1,5-戊二亚基。这些化合物具有强大的增强心肌收缩和减缓心跳速率的活性。由于它们不具有毒性，因此它们可用作心脏强效药物。

  公开号：

  US05919806A1

文献信息

• Pyrano derivatives, a process for their preparation and their use
  申请人：Beecham Group Limited

  公开号：US04327099A1

  公开（公告）日：1982-04-27

  Compounds of the formula (I): ##STR1## wherein R.sub.1 and R.sub.2 are independently selected from a hydrogen atom and a C.sub.1-3 alkyl group; R.sub.3 is a hydrogen atom, a C.sub.1-3 alkyl or C.sub.2-4 acyl group; R.sub.4 is a hydrogen atom or C.sub.1-5 alkyl group; R.sub.5 is a C.sub.1-5 alkyl group, a straight chain C.sub.1-3 alkyl group terminally substituted by a chlorine atom; or R.sub.4 and R.sub.5 are joined so that together with the nitrogen atom to which they are attached they form a 5-, 6- or 7-membered ring optionally containing an oxygen or sulphur atom; R.sub.6 is a hydrogen atom, or a C.sub.1-5 alkyl, phenyl, CF.sub.3 or XH group wherein X is an oxygen or sulphur atom, the dotted line represents a bond, and R.sub.7 is not present; or R.sub.6 is an oxygen atom joined to the ring carbon atom by a double bond, the dotted line is not present, and R.sub.7 is hydrogen; the NR.sub.4 R.sub.5 and OR.sub.3 moieties are trans; and pharmaceutically acceptable salts thereof having antihypertensive activity, processes for their preparation and their use in compositions.

  式（I）的化合物：其中R.sub.1和R.sub.2分别从氢原子和C.sub.1-3烷基组中选择；R.sub.3是氢原子，C.sub.1-3烷基或C.sub.2-4酰基；R.sub.4是氢原子或C.sub.1-5烷基；R.sub.5是C.sub.1-5烷基，一条直链C.sub.1-3烷基末端被氯原子取代；或R.sub.4和R.sub.5连接在一起，与它们附着的氮原子一起形成一个含有氧原子或硫原子的5、6或7元环；R.sub.6是氢原子，或C.sub.1-5烷基、苯基、CF.sub.3或XH组，其中X是氧原子或硫原子，虚线表示键，R.sub.7不存在；或R.sub.6是通过双键连接到环碳原子的氧原子，虚线不存在，R.sub.7是氢；NR.sub.4R.sub.5和OR.sub.3基团为反式；及其具有降压活性的药用盐，其制备方法及其在配方中的使用。
• Chromanol derivatives, a process for their preparation and a pharmaceutical composition comprising them
  申请人：BEECHAM GROUP PLC

  公开号：EP0028064A1

  公开（公告）日：1981-05-06

  Compounds of the formula (I): and salts and pro-drugs thereof, wherein: R1 is a hydrogen atom or a lower alkyl group: R2 is a hydrogen atom or a lower alkyl group: R3 is a hydrogen atom or a lower alkyl group; R4 is a hydrogen atom or an alkyl group; R5 is a lower alkyl or a substituted alkyl group; or R4 and R5 are joined so that together with the nitrogen atom to which they are attached they form a 5-, 6- or 7-membered ring optionally containing an oxygen or sulphur atom: R6 is an electron donating group; R7 is an electron withdrawing group; and the NR4R5 and OR3 moieties are trans having antihypertensive activity, pharmaceutical compositions containing them and processes for their preparation.

  式(I)化合物： 及其盐类和原药，其中 R1 是氢原子或低级烷基 R2 是氢原子或低级烷基 R3 是氢原子或低级烷基 R4 是氢原子或烷基 R5 是低级烷基或取代的烷基； 或 R4 和 R5 连接在一起，与所连接的氮原子一起形成一个 5、6 或 7 元环，环上可选含有一个氧原子或硫原子： R6 是电子捐赠基团； R7 是取电子基团；而 NR4R5 和 OR3 分子是具有抗高血压活性的反式、含有它们的药物组合物及其制备工艺。
• Pyrano derivatives, a process for their preparation and antihypertensive compositions containing them
  申请人：BEECHAM GROUP PLC

  公开号：EP0033612A1

  公开（公告）日：1981-08-12

  Compounds of the formula (I): wherein R1 and R2 are independently selected from a hydrogen atom and a C1-3 alkyl group; R3 is a hydrogen atom, a C1-3 alkyl or C2-4 acyl group; R, is a hydrogen atom or C1-5 alkyl group; R5 is a C1-5 alkyl group, a straight chain C1-3 alkyl group terminally substituted by a chlorine atom; or R4 and R5 are joined so that together with the nitrogen atom to which they are attached they form a 5-, 6- or 7-membered ring optionally containing an oxygen or sulphur atom; R6 is a hydrogen atom, or a C1-5 alkyl, phenyl, CF3 or XH group wherein X is an oxygen orsulphur atom, the dotted line represents a bond, and R, is not present; or R6 is an oxygen atom joined to the ring carbon atom by a double bond, the dotted line is not present, and R7 is hydrogen; the NR4R5 and OR3 moieties are trans; and pharmaceutically acceptable salts thereof having antihypertensive activity, processes for their preparation and their use in compositions.

  式 (I) 的化合物： 其中 R1 和 R2 分别独立地选自氢原子和 C1-3 烷基； R3 是氢原子、C1-3 烷基或 C2-4 丙烯酸基； R是氢原子或C1-5烷基 R5 是 C1-5 烷基、被氯原子末端取代的直链 C1-3 烷基；或 R4 和 R5 连接在一起，与所连接的氮原子一起形成一个 5、6 或 7 元环，环上可选含有一个氧原子或硫原子； R6 是氢原子，或 C1-5 烷基、苯基、CF3 或 XH 基团，其中 X 是氧原子或硫原子，虚线代表键，且 R 不存在；或 R6 是通过双键与环碳原子相连的氧原子，虚线不存在，且 R7 是氢； NR4R5和OR3分子为反式；及其具有抗高血压活性的药学上可接受的盐类、其制备工艺和在组合物中的用途。
• HEART FAILURE REMEDY
  申请人：NISSAN CHEMICAL INDUSTRIES, LIMITED

  公开号：EP0693283A1

  公开（公告）日：1996-01-24

  A cardiotonic containing a compound represented by general formula (I) or, if any, a pharmaceutically acceptable salt thereof as the active ingredient, wherein X¹ and X² are absent or each represents oxygen; A represents OH or C₁-C₄ acyloxy; B represents hydrogen or is combined with A to form a bond; X represents oxygen, nitrogen, sulfur, etc.; R¹ and R² represent each hydrogen, C₁ - C₄ alkyl, etc.; and R³ and R⁴ represent each hydrogen, C₁ - C₄ alkyl, etc., or they may be combined together to represent 1,4-butylene, 1,5-pentylene, etc. The compound has potent activities of increasing cardiac contractility and reducing cardiac rate and is lowly toxic, thus being useful as a cardiotonic.

  一种含有通式(I)代表的化合物或其药学上可接受的盐(如有)作为活性成分的强心剂，其中 X¹ 和 X² 不存在或各自代表氧；A 代表 OH 或 C₁-C₄酰氧基；B 代表氢或与 A 结合形成键；X 代表氧、氮、硫等；R¹ 和 R² 各自代表氢、C₁ -C₄ 烷基等；以及 R³ 和 R⁴ 各自代表氢、C₁ -C₄ 烷基等。R¹ 和 R² 分别代表氢、C₁-C₄ 烷基等；R³ 和 R⁴ 分别代表氢、C₁-C₄ 烷基等、或将它们组合在一起代表 1,4-丁烯、1,5-戊烯等。该化合物具有增强心脏收缩力和降低心率的强效活性，毒性低，因此可用作强心剂。
• JPH024791A
  申请人：——

  公开号：JPH024791A

  公开（公告）日：1990-01-09